ImmuCell Corporation plans to release Q1 2025 financial results on May 14 and host a conference call May 15.
Quiver AI Summary
ImmuCell Corporation, an animal health company focused on improving the health and productivity of dairy and beef cattle, announced it will release its unaudited financial results for the first quarter of 2025 on May 14, 2025, after market close. A conference call to discuss these results is scheduled for May 15, 2025, at 9:00 AM ET, accessible via provided phone numbers. The company emphasizes that it does not anticipate changes to its preliminary sales figures disclosed earlier. Following the financial results, ImmuCell plans to submit its Quarterly Report on Form 10-Q and will update its Corporate Presentation slide deck, available on its website. ImmuCell is known for products like First Defense®, which provides immediate immunity for newborn calves, and is also developing Re-Tain®, a treatment for mastitis in dairy cows.
Potential Positives
- ImmuCell is set to report its unaudited financial results for Q1 2025 on May 14, 2025, indicating transparency and timely communication with investors.
- The company anticipates no change in its preliminary sales results disclosed earlier, suggesting stability in its financial performance.
- ImmuCell's product developments, including Re-Tain® for mastitis treatment, reflect ongoing innovation and commitment to improving animal health.
- The upcoming conference call on May 15, 2025, provides an opportunity for direct engagement with investors, fostering a responsive relationship with stakeholders.
Potential Negatives
- The company is only providing unaudited financial results, which may lead to concerns about transparency and reliability of the reported figures.
- The anticipation of no change to preliminary sales results may indicate stagnation or lack of growth, which could negatively impact investor confidence.
- The upcoming financial results will be communicated after market closure, potentially causing volatility in stock price due to investor reactions post-announcement.
FAQ
When will ImmuCell report its financial results?
ImmuCell expects to report unaudited financial results for the quarter ended March 31, 2025, after the market closes on May 14, 2025.
How can I join the ImmuCell conference call?
To join the conference call on May 15, 2025, dial (844) 855-9502 (toll free) or (412) 317-5499 (international) at 9:00 AM ET.
What is the replay information for the conference call?
A teleconference replay will be available until May 22, 2025, at (877) 344-7529 (toll free) or (412) 317-0088 (international) using the replay access code #4755970.
Where can I find ImmuCell's updated Corporate Presentation?
The updated Corporate Presentation slide deck will be available on the "Investors" tab of ImmuCell's website after the market closes on May 14, 2025.
What products does ImmuCell specialize in?
ImmuCell develops products like First Defense®, which provides Immediate Immunity™, and is working on Re-Tain®, a treatment for subclinical mastitis in dairy cows.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ICCC Hedge Fund Activity
We have seen 5 institutional investors add shares of $ICCC stock to their portfolio, and 9 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CRESSET ASSET MANAGEMENT, LLC removed 132,001 shares (-50.0%) from their portfolio in Q4 2024, for an estimated $679,805
- CITADEL ADVISORS LLC added 29,021 shares (+inf%) to their portfolio in Q4 2024, for an estimated $149,458
- NORTHERN TRUST CORP added 14,982 shares (+51.0%) to their portfolio in Q4 2024, for an estimated $77,157
- RENAISSANCE TECHNOLOGIES LLC removed 12,500 shares (-8.4%) from their portfolio in Q4 2024, for an estimated $64,375
- MESIROW FINANCIAL INVESTMENT MANAGEMENT, INC. removed 12,178 shares (-50.0%) from their portfolio in Q1 2025, for an estimated $58,332
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 11,604 shares (+inf%) to their portfolio in Q4 2024, for an estimated $59,760
- GEODE CAPITAL MANAGEMENT, LLC added 7,878 shares (+13.9%) to their portfolio in Q4 2024, for an estimated $40,571
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
PORTLAND, Maine, May 12, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended March 31, 2025 after the market closes on Wednesday, May 14, 2025.
The Company is planning to host a conference call the next morning, Thursday, May 15, 2025, at 9:00 AM ET to review the unaudited financial results. Interested parties can access the conference call by dialing (844) 855-9502 (toll free) or (412) 317-5499 (international) at 9:00 AM ET. A teleconference replay of the call will be available until May 22, 2025 at (877) 344-7529 (toll free) or (412) 317-0088 (international), utilizing replay access code #4755970.
The Company anticipates no change to the preliminary sales results for the first quarter ended March 31, 2025 that were disclosed on April 8, 2025. The Company expects to file its Quarterly Report on Form 10-Q on May 14, 2025 after the market closes.
Investors are encouraged to review the Company’s updated Corporate Presentation slide deck that provides an overview of the Company’s business which can be accessed under the “Investors” tab of the Company’s website at www.immucell.com , or by request to the Company. An updated version of the slide deck will be made available after the market closes on Wednesday, May 14, 2025.
About ImmuCell:
ImmuCell Corporation's (
Nasdaq: ICCC
) purpose is to create scientifically proven and practical products that improve the health and productivity of dairy and beef calves. ImmuCell manufactures and markets
First Defense
®
, which provides
Immediate Immunity
™ to newborn dairy and beef calves, and is developing
Re-Tain
®
, a novel treatment for subclinical mastitis in dairy cows without FDA-required milk discard or pre-slaughter withdrawal label restrictions that provides an alternative to traditional mastitis antibiotics. Press releases and other information about the Company are available at:
http://www.immucell.com
.
|
Contacts:
|
Michael F. Brigham, President and CEO |
| Timothy C. Fiori, Chief Financial Officer | |
| ImmuCell Corporation | |
| (207) 878-2770 | |
| Joe Diaz, Robert Blum and Joe Dorame | |
| Lytham Partners, LLC | |
| (602) 889-9700 | |
| [email protected] |
